Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pediatr.

Sec. Pediatric Oncology

Volume 13 - 2025 | doi: 10.3389/fped.2025.1595223

Venous Thromboembolism Risk Factors in Pediatric High-Grade Glioma: A Multicenter Retrospective Study

Provisionally accepted
Yanxia  ChenYanxia Chen1Wenjing  FeiWenjing Fei2Yaqin  ShiYaqin Shi1Weiwei  MaWeiwei Ma1Wei  JiaoWei Jiao1Fengqin  TaoFengqin Tao1Jie  ZhuJie Zhu1Yuhai  WangYuhai Wang1Xiaoyan  FengXiaoyan Feng1*
  • 1Anhui Medical University, Hefei, China
  • 2Nanjing Medical University, Nanjing, Jiangsu Province, China

The final, formatted version of the article will be published soon.

Background: Venous Thromboembolism (VTE) is a significant complication in pediatric high-grade glioma (pHGG) patients, impacting prognosis and treatment outcomes. Identifying unique risk factors and pathophysiology in children is essential for targeted prevention and treatment.: A multicenter retrospective analysis was conducted on pHGG patients enrolled between January 2012 and January 2024 at two hospitals. Data were collected from electronic medical records and follow-ups, focusing on VTE occurrence, clinical characteristics, and treatment outcomes. Statistical analyses included t-tests, Mann-Whitney U tests, chi-square tests, and Cox regression models to identify risk factors and their impact on survival. Results: Out of 216 screened patients, 168 met the inclusion criteria. The mean age was 9.87±3.67 years, with 37.5% experiencing VTE. Tumor volume, grade, and specific genetic mutations significantly influenced VTE occurrence. Anticoagulation therapy, Isocitrate Dehydrogenase 1 (IDH1) mutations, O6-Methylguanine-DNA Methyltransferase (MGMT) methylation, radiotherapy, chemotherapy, and prolonged bed rest were protective against VTE, while increased tumor volume, Grade 4 glioma, Epidermal Growth Factor Receptor (EGFR) positivity, p53 mutations, glucocorticoid therapy and central venous catheter placement (CVCP) placement promoted VTE risk. The median survival time was 51.4 months, and VTE occurrence negatively impacted patient prognosis.This study highlights the risk factors for VTE in pHGG patients, emphasizing the need for tailored prevention and treatment strategies. The findings underscore the importance of clinical characteristics, genetic profiles, and treatment modalities in managing VTE and improving survival outcomes in pHGG.

Keywords: pediatric high-grade glioma, Venous Thromboembolism, Risk factors, Anticoagulation therapy, Survival outcomes

Received: 17 Mar 2025; Accepted: 22 Jul 2025.

Copyright: © 2025 Chen, Fei, Shi, Ma, Jiao, Tao, Zhu, Wang and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xiaoyan Feng, Anhui Medical University, Hefei, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.